Bethany Mancilla

Bethany Mancilla's work experience includes positions in various biotech and pharmaceutical companies. Bethany is currently the Chief Business Officer at Capsida Biotherapeutics since February 2020. Prior to this, they served as the Vice President of Corporate Development at Kite Pharma, a Gilead Company, from May 2019 to October 2019. Bethany was also the Chief Business Officer at Cue Biopharma from August 2018 to April 2019.

Before joining Cue Biopharma, Bethany held multiple roles at Amgen. Bethany was a Vice President from January 2016 to July 2018, where they assessed and executed licensing, co-development, and M&A opportunities. During their time at Amgen, they were recognized as a top woman at the company. Before that, they served as an Executive Director in Licensing External R&D from April 2012 to January 2016.

Bethany also worked at Micromet, Inc. as the VP of Business Development & Alliance Management from April 2010 to April 2012. Bethany negotiated a significant collaboration with Amgen, leading to Micromet's acquisition. Additionally, they established alliance management capabilities for collaborations with various companies.

Prior to Micromet, Bethany held the position of VP of Business Development and Licensing at PharmAthene from February 2008 to April 2010. Bethany was responsible for strategic alliances with Bristol Myers Squibb and negotiated a distribution agreement with Medison Pharma.

Bethany'scareer began at Baylor College of Medicine Technologies, where they served as the Director of Business Development from 1990 to 1993. Bethany also held the role of VP of Business Development at Gene Logic from 1998 to 2008.

In summary, Bethany Mancilla has extensive experience in corporate development, business strategy, financing, and licensing within the biotech and pharmaceutical industries.

Bethany Mancilla pursued their education in a chronological manner, beginning with their BA degree in Biopsychology from the University of Colorado Boulder. Bethany attended this university from 1981 to 1985. Following this, they furthered their education by pursuing an MBA degree in Finance from the University of Houston, studying from 1987 to 1990.